SCHEDULE: Vanguard Group Discloses 10.03% Passive Stake in AbbVie Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in AbbVie Inc. as of June 30, 2025.

Summary

• The Vanguard Group, an investment adviser based in Pennsylvania, has filed an Amendment No. 11 to Schedule 13G regarding its beneficial ownership in AbbVie Inc.
• As of June 30, 2025, The Vanguard Group beneficially owns an aggregate of 177,266,703 shares of AbbVie Inc. Common Stock.
• This ownership represents 10.03% of the class of securities.
• The Vanguard Group holds sole voting power over 0 shares, shared voting power over 2,360,296 shares, sole dispositive power over 168,246,961 shares, and shared dispositive power over 9,019,742 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of AbbVie Inc.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of a significant passive ownership stake by a major institutional investor, The Vanguard Group, in AbbVie Inc. This indicates continued institutional confidence in the company, without implying any active strategic or control-oriented intentions.

Positives

• The disclosure of a significant 10.03% passive stake by a major institutional investor like The Vanguard Group indicates continued institutional confidence in AbbVie Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding AbbVie Inc.'s future performance or strategic outlook.

Management Comments

• The Vanguard Group certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of AbbVie Inc.

Industry Context

This filing represents a routine disclosure by a major institutional asset manager, The Vanguard Group, regarding its passive investment in a leading pharmaceutical company, AbbVie Inc. Such significant institutional holdings are common for large, established companies within the healthcare and pharmaceutical sectors, reflecting their inclusion in broad market indices and investment portfolios.

Comparison to Industry Standards

• The Vanguard Group's 10.03% stake in AbbVie Inc. is a substantial holding, typical for a large passive investment manager like Vanguard, which often holds significant percentages across numerous publicly traded companies as part of its index-tracking and diversified fund strategies.
• This level of ownership is consistent with the passive investment approach of large fund groups, which generally do not seek to influence corporate control, aligning with the certification provided in the filing.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional ownership, potentially reinforcing confidence due to a large, passive investor holding a substantial stake in the company.

Next Steps

• AbbVie Inc. will continue its regular business operations and financial reporting.
• The Vanguard Group will continue to hold its investment in AbbVie Inc. in the ordinary course of business, subject to its investment strategies and market conditions.

Key Dates

Recommendation

Keywords

AbbVie Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Pharmaceutical, Biotech